Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of hypertension and heart failure, particularly in patients who cannot tolerate oral medication. As the active… Read more
Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of hypertension and heart failure, particularly in patients who cannot tolerate oral medication. As the active metabolite of enalapril, this compound is primarily administered intravenously. The following category provides pharmaceutical reference standards for Enalaprilat, including the active pharmaceutical ingredient, pharmacopeial and non-pharmacopeial impurities, and stable isotope-labelled compounds. These materials are essential for laboratories conducting rigorous analytical testing, impurity profiling, and method validation. The inclusion of stable isotope-labelled versions, such as deuterated analogues, facilitates precise quantitative analysis through mass spectrometry, while impurity standards support system suitability testing and comprehensive quality control. These reference materials help ensure regulatory compliance and the consistent performance of analytical methods throughout the pharmaceutical development and manufacturing lifecycle.